Hematopoietic Stem Cell TransplantationTransplantation, HomologousHematopoietic Stem CellsGraft vs Host DiseaseTransplantation ConditioningHematologic NeoplasmsStem CellsTransplantation, AutologousStem Cell TransplantationGraft vs Leukemia EffectTransplantation ChimeraTissue DonorsBone Marrow TransplantationGraft vs Tumor EffectMyeloablative AgonistsHematopoiesisTreatment OutcomeWhole-Body IrradiationChimerismBusulfanAllograftsLeukemiaHistocompatibilityPeripheral Blood Stem Cell TransplantationRecurrenceHematologic DiseasesVidarabineGraft SurvivalRetrospective StudiesBone Marrow CellsHistocompatibility TestingMyelodysplastic SyndromesHematopoietic Stem Cell MobilizationLeukemia, Myeloid, AcuteCell DifferentiationAntigens, CD34Flow CytometryCell LineageLymphocyte TransfusionStem Cell NicheMice, Inbred C57BLCord Blood Stem Cell TransplantationSiblingsCytomegalovirus InfectionsAdult Stem CellsEmbryonic Stem CellsT-LymphocytesHLA AntigensPrecursor Cell Lymphoblastic Leukemia-LymphomaTime FactorsCystitisLeukemia, Myelogenous, Chronic, BCR-ABL PositiveRemission InductionColony-Forming Units AssayAcute DiseaseFetal BloodImmunosuppressive AgentsSurvival RateHepatic Veno-Occlusive DiseaseLeukemic InfiltrationCells, CulturedOpportunistic InfectionsSurvival AnalysisMinor Histocompatibility AntigensTransplantation, IsogeneicAnemia, AplasticTransplantation ImmunologyBone MarrowStem Cell FactorLymphocyte DepletionPluripotent Stem CellsCombined Modality TherapyMultipotent Stem CellsCytomegalovirusNeoplasm, ResidualCell SeparationSevere Combined ImmunodeficiencyDisease-Free SurvivalLymphoproliferative DisordersIsoantigensFollow-Up StudiesCyclophosphamideCell ProliferationBronchiolitis ObliteransMycosesSalvage TherapyPhotopheresisMesenchymal Stromal CellsLeukemia, MyeloidImmunocompromised HostHematopoietic SystemBlood Transfusion, AutologousPrimary MyelofibrosisMultiple MyelomaMice, SCIDRisk FactorsInduced Pluripotent Stem CellsImmunophenotypingMesenchymal Stem Cell TransplantationAntilymphocyte Serum